Gomekli
SpringWorks Therapeutics Secures FDA Approval for Gomekli to Treat NF1-Related Tumors
SpringWorks Therapeutics, Gomekli, mirdametinib, FDA approval, neurofibromatosis type 1 (NF1), plexiform neurofibromas (PN), rare disease treatment, MEK inhibitor
FDA Approves SpringWorks’ Gomekli for Adult and Pediatric NF1-PN Patients
Gomekli, mirdametinib, neurofibromatosis type 1, plexiform neurofibromas, FDA approval, SpringWorks Therapeutics, MEK inhibitor
Merck KGaA in Advanced Talks to Acquire SpringWorks Therapeutics, Bolstering Oncology Portfolio
Merck KGaA, SpringWorks Therapeutics, acquisition, oncology, rare diseases, Ogsiveo, Gomekli, pharmaceutical industry